Stockreport

Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE

Astria Therapeutics, Inc.  (ATXS) 
PDF -- Single Pivotal Trial Designed to Demonstrate Efficacy and Safety of Every 3- and Every 6-Month Administration in a 6-Month Treatment Period ---- Pioneering Patient-Ce [Read more]